Evans, James W.
Revolution Medicines (United States)
7 papers on CoChatORCID 0009-0005-0401-6397
Most cited papers
- Verified
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Holderfield, M., Lee, B. J., Jiang, J., Tomlinson, A., Seamon, K. J., Mira, A., Patrucco, E., Goodhart, G., Dilly, J., Gindin, Y., et al. (2024) · Nature
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 369
- Verified
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 343
- Verified
Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Jiang, L., Menard, M., Weller, C., Wang, Z., Burnett, L., Aronchik, I., Steele, S., Flagella, M., Zhao, R., Evans, J. W. W., et al. (2023) · Cancer Research
Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways
Cited by 76
- Verified
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
Burnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., et al. (2023) · Journal of Medicinal Chemistry
PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling
Cited by 72
- Verified
Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
Kitai, H., Choi, P. H., Yang, Y. C., Boyer, J. A., Whaley, A., Pancholi, P., Thant, C., Reiter, J., Chen, K., Markov, V., et al. (2024) · Nature Communications
PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling
Cited by 41
- Verified
Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor
Koltun, E. S., Rice, M. A., Gustafson, W. C., Wilds, D., Jiang, J., Lee, B. J., Wang, Z., Chang, S., Flagella, M., Mu, Y., et al. (2022) · Cancer Research
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 34
- Verified
Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor.
Gustafson, W. C., Wildes, D., Rice, M. A., Lee, B. J., Jiang, J., Wang, Z., Chang, S., Flagella, M., Mu, Y., Dinglasan, N., et al. (2022) · Journal of Clinical Oncology
Protein Kinase Regulation and GTPase SignalingPancreatic and Hepatic Oncology Research
Cited by 28
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free